These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 10597862)
1. Assessing the cardiac safety of ebastine. Prologue. Roberts DJ Drug Saf; 1999; 21 Suppl 1():1-3. PubMed ID: 10597862 [No Abstract] [Full Text] [Related]
2. Assessing the cardiac safety of ebastine. Epilogue. Roberts DJ Drug Saf; 1999; 21 Suppl 1():89-92. PubMed ID: 10597871 [No Abstract] [Full Text] [Related]
3. [Cardiac arrest following treatment with non-cardiologic QT-interval-increasing medications]. Al-Amood S; Elming H Ugeskr Laeger; 2005 May; 167(18):1966-8. PubMed ID: 15929273 [No Abstract] [Full Text] [Related]
4. [Torsade de pointes: a new way to kill drugs]. Tamargo Menéndez LJ An R Acad Nac Med (Madr); 1998; 115(1):23-42; discussion 42-6. PubMed ID: 9741134 [No Abstract] [Full Text] [Related]
5. Safety of ebastine. Cadahía A; Cardona V; Guilarte M; Muñoz-Cano R Ann Allergy Asthma Immunol; 2005 Mar; 94(3):407. PubMed ID: 15801255 [No Abstract] [Full Text] [Related]
6. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. Malik M J Cardiovasc Electrophysiol; 2001 Apr; 12(4):411-20. PubMed ID: 11332559 [TBL] [Abstract][Full Text] [Related]
7. Drug induced QT prolongation and torsades de pointes. Yap YG; Camm AJ Heart; 2003 Nov; 89(11):1363-72. PubMed ID: 14594906 [No Abstract] [Full Text] [Related]
9. Terfenadine should be withdrawn from clinical use. Khilnani G J Assoc Physicians India; 1999 Sep; 47(9):943. PubMed ID: 10778682 [No Abstract] [Full Text] [Related]
10. Torsade de pointes associated with rupatadine. Fité-Mora R Rev Esp Cardiol; 2009 Mar; 62(3):330-1; author reply 332. PubMed ID: 19268083 [No Abstract] [Full Text] [Related]
11. [Long QT-syndrome as a drug-induced side effect]. Pohjola-Sintonen S Duodecim; 1998; 114(19):1891, 1893, 1895. PubMed ID: 11717743 [No Abstract] [Full Text] [Related]
12. Terfenadine, astemizole, and ebastine produce QTc interval prolongation in an experimental model predictive of adverse clinical ECG effects. Hey JA; del Prado M; Egan RW; Kreutner W Ann Allergy Asthma Immunol; 1996 May; 76(5):476. PubMed ID: 8630724 [No Abstract] [Full Text] [Related]
13. [Side effects, unwanted drug interactions and the problem of cardiotoxicity]. Woroń J; Trabka-Janik E; Kostka-Trabka E Przegl Lek; 2003; 60(4):196-8. PubMed ID: 14569882 [TBL] [Abstract][Full Text] [Related]
14. Cardiac effects of ebastine and other antihistamines in humans. Moss AJ; Morganroth J Drug Saf; 1999; 21 Suppl 1():69-80; discussion 81-7. PubMed ID: 10597870 [TBL] [Abstract][Full Text] [Related]
15. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Gillen MS; Miller B; Chaikin P; Morganroth J Br J Clin Pharmacol; 2001 Aug; 52(2):201-4. PubMed ID: 11488779 [TBL] [Abstract][Full Text] [Related]
16. What has the patient been taking? Pasco J Aust Fam Physician; 1998 Jun; 27(6):517. PubMed ID: 9648320 [No Abstract] [Full Text] [Related]
17. Torsades de pointes occurring in association with terfenadine use. Monahan BP; Ferguson CL; Killeavy ES; Lloyd BK; Troy J; Cantilena LR JAMA; 1990 Dec; 264(21):2788-90. PubMed ID: 1977935 [TBL] [Abstract][Full Text] [Related]
18. A review of the cardiac systemic side-effects of antihistamines: ebastine. Moss AJ; Chaikin P; Garcia JD; Gillen M; Roberts DJ; Morganroth J Clin Exp Allergy; 1999 Jul; 29 Suppl 3():200-5. PubMed ID: 10444238 [TBL] [Abstract][Full Text] [Related]